# A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

> **NCT05985161** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 45 (estimated)

## Conditions studied

- Wilms Tumor
- Rhabdoid Tumor
- Malignant Peripheral Nerve Sheath Tumors
- MPNST
- Nephroblastoma
- XPO1 Gene Mutation
- Solid Tumor

## Interventions

- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT05985161
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2029-08-01
- **Final completion:** 2029-08-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05985161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05985161, "A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05985161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*